Long-term Muscle Synthetic Effects of Intradialytic Parenteral Nutrition in Chronic Hemodialysis Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Myofibrillar fractional synthetic rate
研究概览
简要总结
This study examines the effects of intradialytic parenteral nutrition (IDPN) on muscle growth and blood pressure in patients undergoing chronic hemodialysis.
详细描述
Rationale: Malnutrition and a negative protein balance are highly prevalent in hemodialysis (HD) patients. In these patients, nutritional status and body composition are closely linked to morbidity, mortality, and quality of life. Muscle wasting in HD patients is the result of poor intake, anabolic resistance and the intradialytic loss of amino acids, leading to a negative protein balance. Intradialytic parenteral nutrition (IDPN) has been shown to reverse this anabolic state in the short term (a single dialysis session) in studies using primed constant infusion of isotope-labeled amino acids. However, such studies were carried out in fasted state, which may significantly overestimate the effect. Moreover, they provide no insight in muscle synthesis over longer periods of time, including the interdialytic interval and across multiple dialysis sessions. The use of deuterated water (2H2O) enables longer-term assessment of muscle protein synthesis in an outpatient setting. The administration of IDPN, due to its volume, may have intradialytic hemodynamic effects, which have not been characterized in previous studies.
Objective: To study the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to characterize the hemodynamic effects of IDPN.
Study design: Investigator-initiated intervention study with crossover design.
Study population: Chronic hemodialysis patients aged over 18 years (dialysis vintage over 3 months).
Intervention: IDPN (Olimel N12, Baxter, 1L/session) or regular care without IDPN.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age above 18 years
- •Receiving HD treatment over 3 months
- •Receiving HD treatment 3 times per week for at least 4 hours per session
- •24-hour urine production < 100 mL
- •Adequate dialysis dose (eKt/V over 1.2)
- •AV fistula with blood flow (measured invasively or by Doppler ultrasound) over 750 mL/min
排除标准
- •Occurrence of intradialytic hypotension in the last month, defined by systolic blood pressure < 90 mm Hg combined with a nursing intervention
- •Hospitalization < 3 months before inclusion
- •Active infection or inflammation at randomization
- •Use of oral or intravenous corticosteroids
- •Incapacitation
- •Patients who are not expected to be able to complete the study protocol (e.g., due to a planned kidney transplantation within the planned study time frame)
- •Pregnancy
- •Use of oral anticoagulants or antiplatelet agents that cannot be safely stopped during the study
- •Diabetes mellitus
- •AV fistula with recirculation
研究组 & 干预措施
intra dialytic parenteral nutrition (Olimel N12, Baxter, 1L/session)
intra dialytic parenteral nutrition (Olimel N12, Baxter, 1L/session)
干预措施: intra dialytic parenteral nutrition (Olimel N12, Baxter, 1L/session) (Dietary Supplement)
Control
no intervention according to usual care
结局指标
主要结局
Myofibrillar fractional synthetic rate
时间窗: At baseline and during the first dialysis sessions in the following two weeks.
Difference in myofibrillar fractional synthetic rate during treatment with IDPN versus usual care
次要结局
- Forearm amino acid (AA) balance(During the first visit in intervention and cross-over usual care regiment.)
- Intradialytic blood pressure and cardiac output(Cardiac output will be measured at baseline and during the first dialysis sesions in the following 2 weeks. Predialysis systolic blood pressure, intradialytic blood pressure decrease, and ultrafiltration volume will be measured at each dialysis session.)
- Amino acid loss in dialysate(Amino acid loss in dialysate will be measured during V2 and V5.)
研究者
Dr. Wesley Visser
Principal investigator, PhD, RD
Erasmus Medical Center